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The stepped care approach for the management of hyperten-
sion was introduced in the first United States National Guide-
lines issued by the National High Blood Pressure Education
Program [1]. Diuretics were indicated as the first step, based
on their efficacy in the first trials of prevention of cardiovascu-
lar disease and because of their better tolerability compared
to the other antihypertensive drugs that were available at that
time, such as the ganglion blocking agents, guanethidine,
hydralazine, and reserpine. These other antihypertensive
drugs were recommended as second and third steps for
patients who were not controlled by diuretics alone.
In the report by the Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure (JNC) in
1984 (JNC-III) [2], the first recommended step was extended
to include β-blockers. Four years later, in the JNC-IV report,
the recommendations were extended further to include four
classes of blood-pressure-lowering drugs [3]. In the subse-
quent guidelines, the Committee returned to diuretics or β-
blockers as the first antihypertensive option, but, because of
the “compelling indications”, the recommendations were
extended to include a wide range of the other classes of
blood-pressure-lowering drugs [4].
The introduction of newer classes of antihypertensive drugs
was based on their presumed better tolerance and on the
expectation that they would improve the prevention of coronary
heart disease, which was lower than expected in the first trials,
mainly attributed to adverse metabolic effects of diuretics.
Physicians around the world became convinced of these
advantages and the use of the newer classes of drugs sur-
passed diuretics and β-blockers for antihypertensive treatment.
The results of recent trials and reanalysis of the previous ones
show that we should return to older practices. Two recent
reviews of these trials have reached opposite conclusions.
Pahor et al., showed that the calcium-channel blockers are
inferior to other antihypertensive drugs [5]. The Blood Pres-
sure Lowering Treatment Trialists’ Collaboration concluded
that any drug with the capacity to lower blood pressure might
be regarded as an efficacious antihypertensive drug, regard-
less of the small differences between classes of drugs that
were observed in some studies [6]. Despite the controversial
revision of almost the same trials [7–12], there are substantial
reasons to believe that diuretics should regain their previous
role as the first drugs to be chosen in the management of
hypertension. These reasons are based on the critical analy-
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Abstract
The results and interpretations of the most recent controlled clinical trials on antihypertensive drugs
have fuelled the debate about the drug that should be used to begin treatment for hypertension. Every
comparison of diuretics with other drugs has shown that the benefits of diuretics are equivalent to, or
better than, other options. These findings, together with other practical reasons, such as left ventricular
mass reducing effect, easy administration, few side effects and low cost, suggest that diuretics should
regain their primacy as the first step in drug management of hypertension.
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sis of both older and new trials on drug treatment of hyper-
tension and on highly practical reasons to choose an antihy-
pertensive drug, such as easiness of administration,
infrequent side effects and price.
What the controlled clinical trials have really
shown
Placebo-controlled studies
Diuretics are the only class of antihypertensive drugs to have
been compared to a placebo in a wide range of hypertensive
diseases. In the first placebo-controlled trial conducted on
severely hypertensive patients, a therapy based on diuretics
provided one of the most significant reductions of the inci-
dence of cardiovascular events [13]. A reanalysis of this study
[14] showed that only six patients per year required treatment
to prevent one major cardiovascular event; this compares
favorably with having to treat 15 patients with heart failure with
an ACE inhibitor in order to prevent one death per year [15],
and needing to treat more than 100 women with a statin per
year to prevent one major cardiovascular event [16]. In at least
16 additional trials (conducted in different countries, on both
men and women, including patients with mild to moderate
hypertension, both under 60 and over 60 years of age, with
and without isolated systolic hypertension), diuretics pre-
vented a wide range of cardiovascular events, including cere-
brovascular disease, coronary heart disease, and heart failure
[17–20]. In the SHEP (Systolic Hypertension in the Elderly
Program) trial [21], during a follow-up averaging four and a
half years, both fatal and nonfatal heart failure occurred in
4.4% of the participants randomized to placebo, and in 2.3%
of those randomized to active therapy (relative risk [RR] 0.51,
95% confidence interval [CI] 0.37–0.71).
The prevention of coronary events in the first trials of diuretics
was lower than expected. This was initially attributed to
adverse effects of thiazide diuretics on the metabolism of
carbohydrates, uric acid and electrolytes. The risk of cardiac
arrhythmias, and sudden death, attributed to the use of higher
doses of thiazide diuretics (which were not antagonized in
their effects on potassium metabolism by potassium-sparing
diuretics), however, was the probable reason for the insuffi-
cient prevention of coronary events [22].
In trials with elderly (older than 60 years) participants
[18–20], with a therapy based on lower doses of thiazide
diuretics (in most instances associated with a potassium-
sparing agent), the magnitude of prevention of coronary
events came closer to that predicted by cohort studies.
Taking together these and older studies, and reclassifying the
participants by the drug used as the first option, Psaty et al.,
confirmed the superiority of low doses of thiazide diuretics
[23]. Only diuretics at lower doses were effective in prevent-
ing both cerebrovascular and coronary events. This is a pecu-
liar situation in terms of drug therapy, that lower doses have a
better effect. The ineffectiveness of β-blockers was unex-
pected, because they are efficacious in the secondary pre-
vention of myocardial infarction. In the first trials, when the
effects of diuretics and β-blockers were evaluated together,
the unexpectedly lower rates of prevention may be due to the
lower efficacy of β-blockers.
Only one agent of other antihypertensive groups, nitrendipine,
has been shown to be superior to placebo in a large trial with
clinical endpoints [24]. The effect observed in that study, with
elderly participants with isolated systolic hypertension, was
very similar to that observed in the North American trial with a
similar design, which used a thiazide-like diuretic as the first
option [18]. In both trials the number requiring treatment to
prevent any fatal or nonfatal cardiovascular event was 100
patients per year. An angiotensin-converting-enzyme (ACE)
inhibitor was shown to be superior to placebo in patients with
evidence of ischemic heart disease or diabetes, but only a
proportion of them had hypertension [25].
Trials comparing the effect of different
antihypertensive drugs on clinical endpoints
The results of several trials comparing agents from the differ-
ent antihypertensive groups were published recently. In the
CAPPP (Captopril Prevention Project) trial [26], the open
design without a centralized randomization of patients
involved a systematic allocation of an unknown proportion of
participants to captopril or to the control group, a fact that
raises questions about the inclusion of this study in the cate-
gory of randomized trials. Nevertheless, this trial showed that
similar effects on a combined cardiovascular endpoint could
be achieved with a therapy based on either captopril, diuret-
ics, or β-blockers. Among the a priori defined secondary end-
points, the only statistically significant supremacy was of the
conventional therapy over captopril in preventing cerebrovas-
cular events, which occurred at a frequency approximately
25% higher in participants randomized to captopril (RR 1.25,
CI 1.01–1.55).
The STOP-2 (Swedish Trial in Old Patients with Hypertension-
2) study compared new therapies (a calcium-channel blocker
or an ACE inhibitor) to older therapies (one of the β-blockers
or a diuretic) in very elderly patients aged 70–84 years [11].
The incidence of clinical endpoints did not differ between the
two general strategies, but the incidence of adverse effects
was more frequent in patients treated with a calcium-channel
blocker or an ACE inhibitor. Since this trial was not designed
to compare individual drugs, some important differences may
have been concealed [27]. β-blockers are known to be less
effective than diuretics, particularly in this age group [19], and
the proportion of patients treated with one of these heteroge-
neous groups was not reported in the publication. Moreover,
pindolol, a β-blocker implicated in coronary risk not only due to
the absence of a protective effect [28], was one of the β-
blockers used by an unknown proportion of patients. This
study also showed that ACE inhibitors were superior to
calcium-channel blockers in terms of prevention of coronary
events and heart failure. In this respect, these results confirmCurrent Controlled Trials in Cardiovascular Medicine    October 2001 Vol 2 No 5  Fuchs
indirect evidence, from a case-control study [29] and a sec-
ondary analysis of clinical trials [7,30], that has implicated
short-acting calcium antagonists in an increased risk of
myocardial infarction. Similarly, a recent trial with African-
American patients with hypertensive renal disease showed
that those allocated to ramipril had 48% fewer clinical end
points (reduction in glomerular filtration rate of more than 50%
or 25 ml/min per 1.73 m2, end-stage renal disease, or death)
than the patients treated with amlodipine [31].
The partial results of the Antihypertensive and Lipid Lowering
treatment to prevent Heart Attack Trial (ALLHAT), designed to
compare drugs from four major classes of antihypertensives,
showed the definite superiority of a diuretic over an α-blocker
[32]. Despite the similar effect on total mortality, patients
treated with doxazosin had a higher incidence of stroke (RR
1.19, 95% CI 1.01–1.40), cardiovascular events (RR 1.25,
95% CI 1.17–1.33), and heart failure (RR 2.04, 95% CI
1.79–2.32), than patients treated with chlorthalidone.
The NORDIL (Nordic Diltiazem) study was another trial that
compared a calcium-channel blocker, diltiazem, with an old-
strategy treatment, (a diuretic or β-blocker) [12]. The inci-
dence of a composite endpoint was virtually identical in both
groups. Patients treated with diltiazem had a lower incidence
of stroke (RR 0.80, 95% CI 0.65–0.99) whilst patients on an
old treatment strategy showed a trend towards a lower inci-
dence of myocardial infarction (RR 1.16, 95% CI 0.94–1.44).
Similarly to the STOP-2 trial, patients in the control group
were mainly treated with one β-blocker, which is not the most
effective antihypertensive agent. More patients in the dilti-
azem group (23%) stopped taking their medication, than
patients in the control group (7%).
INSIGHT (International Nifedipine-GITS Study: Intervention
as a Goal in Hypertension Treatment), a well-designed,
double-blind clinical trial, was the last study to be published
comparing the effect of antihypertensive drugs on hard end-
points [10]. This study showed the superiority of co-amilozide
(a thiazide and a potassium-sparing diuretic) over a gastroin-
testinal, slow-release preparation of nifedipine, in preventing
fatal myocardial infarction (RR 3.22, 95% CI 1.18–8.8), and
in reducing nonfatal heart failure (RR 2.2, 95% CI
1.07–4.49). More patients stopped taking nifedipine (22.9%)
than diuretics (16.3%) because of unbearable side effects,
mainly ankle edema. Among those who tolerated the antihy-
pertensives, some metabolic effects were more common in
patients treated with diuretics.
A new report, based on data from the same cohort that identi-
fied the risk of short-acting nifedipine [29], demonstrated the
superiority of diuretics, over other classes of blood-pressure-
lowering drugs, to prevent stroke [33]. Although this was a
case-control study, and not a clinical trial, it may have
improved the understanding of the effect of antihypertensive
drugs in everyday clinical practice.
Comparison between the effects of antihypertensive
drugs on surrogate and other endpoints
Trials designed to study the effects of antihypertensive drugs
on intermediate and surrogate endpoints also showed the
superiority of diuretics, or at least their equivalence, to other
antihypertensive drugs. Many trials have tested the hypothe-
sis that antihypertensive drugs would have differential effects
on reducing the ventricular mass of hypertensive patients,
since this characteristic is an independent risk factor for coro-
nary events. None of these trials, however, had the sample
size, number of drugs tested, duration or homogeneity of
criteria for ventricular mass evaluation, of the TOHMS (Treat-
ment of Mild Hypertension Study) trial [34]. In this study, only
the group treated with a thiazide diuretic had a greater reduc-
tion of ventricular mass compared to the placebo group.
The TOHMS trial, and studies by Materson et al. [35], and
Philipp et al. [36], were the best-designed trials for the evalu-
ation of secondary effects of antihypertensive drugs. None of
them showed any substantial difference in the effects of
several classes of antihypertensive drugs on blood pressure,
blood lipids, adverse effects, quality of life, or compliance. In
the study by Materson et al., for instance, more patients
stopped taking placebo (6.4%), than diuretics (1.1%), due to
an adverse drug effect [35].
Other reasons that justify the option for
diuretics as first-choice antihypertensive
drugs
The mechanism of action and the pharmacodynamic effects
of drugs were taken as the pharmacological basis of thera-
peutics in the past and are still important, at least, in terms of
drug development. In this regard, diuretics would be consid-
ered an important innovation if they were discovered nowa-
days, since they probably act on the main mechanism of
blood pressure increase. The renal capability to handle the
overload of sodium, characteristic of the diets of most popu-
lations worldwide, seems to establish the blood pressure
level of the individual [37]. Aging, and the natural reduction in
the number of functioning nephrons, exacerbates this
phenomenon, which has been thought to be one of the mech-
anisms responsible for the increased prevalence of hyperten-
sion among the elderly. Independently of the intrinsic or
extrinsic mechanisms responsible for the relative impairment
in sodium excretion in individuals genetically predisposed to
hypertension, or already with hypertension, the thiazide
diuretics exert their main effect by increasing the renal excre-
tion of sodium and water, and consequently lowering blood
pressure. The potassium-sparing diuretics complement the
effect of thiazide diuretics and prevent the potassium losses
induced by them.
There are other very practical reasons justifying the prefer-
ence for diuretics in the management of hypertension. The
majority of antihypertensive drugs can be taken once a day,
since even drugs with short half-lives are presented in slow-releasing formulations. In contrast, diuretics do not need such
formulations, since their main effect is not dependent on
steady blood levels. In trials that identified their effectiveness
in the prevention of cardiovascular disease, thiazide diuretics
were employed once a day, but they may be active even
when taken at 48-hour intervals, at least in terms of blood
pressure control.
Even when diuretics are not employed as the first drug of
choice, it is quite common to combine them with the drug in
use to obtain a better control of blood pressure. On the basis
of the above considerations, it seems more rational to start
with a diuretic, later adding a second drug if necessary. And,
last but not least, diuretics are comparatively inexpensive.
Conclusion
If the historical sequence was inverted, and diuretics were
being introduced on the market nowadays, after calcium-
channel blockers, ACE inhibitors and other antihypertensive
classes of drugs, they would be very easy to promote.
The following is a summary of the advantages of combined
thiazide and potassium-sparing diuretics over other antihyper-
tensive drugs:
1. Active in the main mechanism of blood pressure elevation.
2. Easy administration.
3. Superior to placebo in a wide range of hypertensive dis-
eases (e.g. severe to mild hypertension, isolated systolic
hypertension) in different sex and age strata, in studies
conducted in several countries.
4. More effective at lower doses.
5. Superior to β-blockers in preventing coronary events.
6. Superior to ACE inhibitors in preventing cerebrovascular
disease.
7. Superior to α-blockers in preventing stroke, cardiovascu-
lar events, and heart failure.
8. Superior to dihydropyridine calcium-channel blockers in pre-
venting fatal myocardial infarction, and nonfatal heart failure.
9. Reduces left ventricular mass.
10.Well tolerated in terms of quality of life, with few side effects.
11.Potentiates other antihypertensive drugs.
12.Relatively inexpensive.
Diuretics are the first step in the treatment of most patients
with hypertension and the new clinical trials should focus on
drugs to be added to them as the second step in the man-
agement of hypertension.
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